Veristat is Recognized on the 2022 Inc. 5000 List of America’s Fastest-Growing Private Companies
Veristat, global experts in clinical development, registration and post-marketing solutions proudly announces its recognition once again by Inc. Magazine as one of the 5000 fastest-growing private companies in the United States.
Since its first appearance on the list in 2015, Veristat has significantly expanded in size, geographic reach and service offering to swiftly guide novel therapies through their clinical development process to regulatory approval and commercialization. Veristat’s team of scientific experts works collaboratively with clients in the biotech and pharmaceutical industries to overcome the many challenges associated with bringing to market products that address current medical shortcomings and maintain their good standing.
“Being recognized as one of America’s Fastest-Growing Private Companies is a testament to Veristat’s ability to deliver innovative solutions, bold thinking and versatile engagement models to our clients,” stated Patrick Flanagan, Chief Executive Officer at Veristat. “In 2021, Veristat supported the preparation of marketing applications for 12% of all FDA (Food and Drug Administration) novel drug approvals. Inc. Magazine’s recognition highlights the impact made by the talented team we have at Veristat; supporting client programs to make novel therapies available to patients worldwide. We will continue to make investments in innovative solutions that enable us to serve as a valued and progressive partner for clients worldwide.”
Recent Veristat acquisitions have allowed the organization to expand its capabilities on a global scale across a range of therapeutic areas, from specialized expertise in the field of rare diseases and oncology to innovative solutions that support patient care and improve study efficiencies. Decentralized clinical trial approaches that bring clinical research closer to the patient’s home along with improved technological capacities have become the norm as the clinical development continuum evolves in a post-COVID world. The Company has recently grown its post-marketing solutions to now include public affairs, market access, supply chain, and healthcare compliance.
The companies on the 2022 Inc. 5000 have not only been successful, but have also demonstrated resilience amid supply chain woes, labor shortages, and the ongoing impact of Covid-19. Together, those companies added more than 68,394 jobs over the past three years.
“The accomplishment of building one of the fastest-growing companies in the U.S., in light of recent economic roadblocks, cannot be overstated,” says Scott Omelianuk, editor-in-chief of Inc. “Inc. is thrilled to honor the companies that have established themselves through innovation, hard work, and rising to the challenges of today.”
Complete results of the Inc. 5000, including company profiles and an interactive database that can be sorted by industry, region, and other criteria, can be found at www.inc.com/inc5000.
Veristat, a scientific-minded global clinical research organization (CRO), enables sponsors to solve the unique and complex challenges associated with accelerating therapies through clinical development to regulatory approval. With more than 27 years of experience in clinical trial planning and execution, Veristat is equipped to support any development program.
Veristat's focus on novel drug development has led to success when handling the unknowns that arise across complicated therapeutic areas, such as rare/ultra-rare disease, advanced therapies, oncology, and infectious disease trials. Every day, we apply this knowledge base to solve any clinical program's challenges, from the simplest to the most complex. Veristat has assembled an extraordinary team of experts worldwide who have mastered therapeutic development intricacies, enabling sponsors to succeed in extending and saving lives.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
Lauren L. Brennan, V.P. of Marketing
About Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Survey Reveals Tech Trust Gap Amongst UK Bank Customers3.10.2022 15:38:00 CEST | Press release
New research by Mitek, a global leader in digital identity and digital fraud prevention, and YouGov has found that banking customers’ trust in technology remains low in the United Kingdom. Only half (52%) of UK bank customers feel that technology like artificial intelligence (AI) and biometrics positively impacts their trust in banks, and only 5% would prefer all interactions with AI/automated systems when engaging banks. These findings are based on a survey of more than 2,200 adults across age groups and UK regions. The industry has undergone a rapid digital transformation in the last few years, with Gartner predicting IT spending by banking and investment services firms growing by 6.1% by end of 2022, to US$623 billion worldwide. While nearly eight in 10 (79%) customers are satisfied with their bank’s digital experience (rating it “good”, “very good”, “or “excellent”), banks are in danger of facing a market-driven stalemate in their research and development should the tech trust gap
Bacardi Announces Leadership Moves to Drive Future Growth3.10.2022 15:30:00 CEST | Press release
Bacardi Limited, the largest privately held spirits company in the world, today announces a series of C-suite talent moves within global commercial and finance and the North America business. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221003005330/en/ Pete Carr to become Bacardi Executive Vice President and Global Growth Officer (Photo: Business Wire) CurrentRegional President for North America Pete Carr will take on the newly created role of Executive Vice President and Global Growth Officer. Pete will be responsible for commercial excellence and strategy, route-to-market models, digital commerce, and on-trade relationships for the family-owned spirits business. Pete comes armed to spearhead continued commercial success for Bacardi, with a lifetime of spirits experience and more than eight years at the helm of one of the company’s largest markets. Pete has showcased fearlessness and a founder’s mentality throughout his
SecurityScorecard Teams with HCLTech to Deliver Customers Proactive, Holistic Security Management3.10.2022 15:00:00 CEST | Press release
SecurityScorecard, the global leader in cybersecurity ratings, today announced a strategic partnership with HCLTech, a leading global technology company, to offer combined solutions that provide a holistic approach to security management, improving customers’ ability to see, resolve and communicate risk more effectively. HCLTech offers its customers SecurityScorecard’s leading cybersecurity ratings as part of its Cybersecurity and Governance, Risk, and Compliance (GRC) offering, enabling customers to proactively gain visibility of their vendor ecosystem, and the security posture of each vendor and manage their cybersecurity threat landscape. SecurityScorecard’s services are now integrated with HCLTech’s Cyber Security Fusion Center (CSFC). HCLTech’s managed security services, coupled with Security Scorecard’s platform and rating data, enable customers to proactively monitor, identify, investigate, respond, report, and evaluate cyber risks and recommend best practices to mitigate those
GC Aesthetics Obtains CE Mark for the New LUNA xt™ Anatomical Breast Implant, the First Under MDR3.10.2022 14:30:00 CEST | Press release
GC Aesthetics® (GCA®) a privately-held medical technology company providing aesthetic and reconstructive solutions for women's global healthcare markets is proud to announce the CE approval of the new micro-textured anatomical breast implant LUNA xt™, the first breast implant in the world approved under the new European Medical Device Regulation (MDR). The new LUNA xt™ Anatomical Breast Implant is GC Aesthetics’ latest innovation, which provides an industry-leading response to both surgeon and patient needs in breast reconstruction procedures. It’s unique and proven safe microtextured surface, highly cohesive silicone gel and high-performance shell, is the state-of-the-art option for women who wish to undergo breast procedures, with a reliable and safe device based on 40 years of expertise in the market. “I am proud to launch the first MDR approved breast implant in the market. This is a great accomplishment and a recognition for the work accomplished by our teams. Being the first one
REPLY Accelerates Its Growth in France and Expands Its Skills in the Field of Agile & Digital Transformation With Wemanity3.10.2022 14:27:00 CEST | Press release
REPLY [EXM, STAR: REY] announces today that Wemanity Group, www.wemanity.com, a leader in France and Benelux in agile & digital transformations, has joined Reply network of companies. Founded in 2013 in Paris, and having expanded its activities to Lille, Brussels, Antwerp, The Hague, Luxembourg, and Casablanca, Wemanity's purpose is to reinvent the future of work thanks to Agile, innovation, and cooperation. The group's skills range from new management methods to the design and delivery of digital products. This is how it helps companies making their organizations become customer-centric, in an efficient, agile and sustainable way. Wemanity's clients include the largest French and European groups in all industry sectors, with a predominance in the financial, luxury, retail, media and energy sectors. The investment in Wemanity is part of Reply's international growth strategy. With Wemanity, Reply acquires new skills and a critical size in France. "Wemanity - said Mario Rizzante, Chairma